Institutional investors purchased a net $2.1 million shares of NLNK during the quarter ended June 2014. This may signal that the smart money is gaining interest in this company as the 50.61% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 2.3 Million shares of NewLink Genetics Corp
AXA INVESTMENT MANAGERS UK LTD. Bought 208.5 Thousand shares of NewLink Genetics Corp